To enable HER2.CAR T cells to target two tumor antigens through both CAR and native TCR, Porter et al. developed a binary oncolytic-helper adenovirus expressing an engager molecule (BiTE), IL-12, and PD-L1 antibody. This combination therapy significantly improved tumor control and survival in models of HER2-positive and HER-negative cancer.
- oncolytic viro-immunotherapy, CAR T cell, BiTE molecule, cytokine, checkpoint inhibitor, CD44 variant 6
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Drug Discovery